Search results
Showing 751 to 765 of 1240 results for pain
inconclusive or is inconsistent with other signs of disease activity (for example, pain or markers of inflammation). There is no...
SecurAcath for securing cerebrospinal fluid catheters (MIB107)
NICE has developed a medtech innovation briefing (MIB) on SecurAcath for securing cerebrospinal fluid catheters .
This guideline covers identifying and managing menopause, including in people with premature ovarian insufficiency. It aims to improve the consistency of support and information provided to people experiencing menopause.
NICE has developed a medtech innovation briefing (MIB) on FreeStyle Libre for glucose monitoring .
NICE has developed a medtech innovation briefing (MIB) on the Epidrum for aiding access to the epidural space
We have moved Medical technologies guidance 39 to become HealthTech guidance 488. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Focal therapy using cryoablation for localised prostate cancer (HTG284)
Evidence-based recommendations on focal therapy using cryoablation for localised stage prostate cancer. This involves using freezing (cryotherapy) needles to find and destroy only the cancerous part of the prostate.
View recommendations for HTG284Show all sections
Sections for HTG284
This guideline covers preventing, assessing and managing mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It aims to improve assessment and support for mental health conditions, and help people with learning disabilities and their families and carers to be involved in their care.
Source guidance details Comes from guidance Neuropathic pain in adults: pharmacological management in non-specialist settings Number
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer (TA1130)
Evidence-based recommendations on talazoparib (Talzenna) with enzalutamide (Xtandi) for untreated hormone-relapsed metastatic prostate cancer.
Endoscopic radiofrequency ablation for squamous dysplasia of the oesophagus (HTG346)
Evidence-based recommendations on endoscopic radiofrequency ablation for squamous dysplasia of the oesophagus. This involves using radiofrequency (heat) energy to destroy the abnormal cells and to promote the growth of healthy squamous cells.
The NICE glossary provides brief definitions and explanations of terms used on the website. The terms describe how NICE works and how its guidance is produced.
asymptomatic intracranial bleeding infection cannulation complications pain. Source guidance details Comes from guidance Extracorporeal
Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults who have had previous treatment with a docetaxel-containing regimen.
Omalizumab for treating severe persistent allergic asthma (TA278)
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.